Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells

Cancer Research

Volumn 57, Issue 9, 1997, Pages 1704-1709

  Bohlen, Heribert ^a   Manzke, Oliver ^a   Titzer, Sandra ^a   Lorenzen, Johann ^a   Kube, Dieter ^a   Engert, Andreas ^a   Abken, Hinrich ^a   Wolf, Jürgen ^a   Diehl, Volker ^a   Tesch, Hans ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; CD19 ANTIGEN; CD28 ANTIGEN; INTERLEUKIN 10; LYMPHOCYTE ANTIBODY; OKT 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GENE REARRANGEMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; T LYMPHOCYTE; T LYMPHOCYTE RECEPTOR GENE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD19; ANTIGENS, CD28; ANTIGENS, CD3; DNA, VIRAL; FLOW CYTOMETRY; GENE REARRANGEMENT, GAMMA-CHAIN T-CELL ANTIGEN RECEPTOR; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOTHERAPY; LYMPHOMA, B-CELL; MICE; MICE, SCID; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; SURVIVAL ANALYSIS; T-LYMPHOCYTES;

EID: 15644384495     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Andersen, P. M., Crist, W., Hasz, D., Carroll, A. J., Myers, D. E., and Uckun, F. M. G19.4(alpha CD3) × B43(alpha CD19) monoclonal antibody heteroconjugate triggers CD19 antigen-specific lysis of t(4;11) acute lymphoblastic leukemia cells by activated CD3 antigen-positive cytotoxic T cells. Blood, 80: 2826-2834, 1992.
2. Nitta, T., Sato, K., Yagita, H., Okumura, K., and Ishii, S. Preliminary trial of specific targeting therapy against malignant glioma. Lancet, 335: 368-371, 1990.
3. Brissinck, J., Demanet, C., Moser, M., Leo, O., and Thielemans, K. Treatment of mice bearing BCL1 lymphoma with bispecific antibodies. J. Immunol., 147: 4019-4026, 1991.
4. Demanet, C., Brissinck, J., Van, M. M., Leo, O., and Thielemans, K. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype × anti-CD3). J. Immunol., 147: 1091-1097, 1991.
5. Demanet, C., Brissinck, J., Leo, O., Moser, M., and Thielemans, K. Role of T-cell subsets in the bispecific antibody (anti-idiotype × anti-CD3) treatment of the BCL1 lymphoma. Cancer Res., 54: 2973-2978, 1994.
6. Weiner, G. J., and Hillstrom, J. R. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma. J. Immunol., 147: 4035-4044, 1991.
7. Ferrini, S., Prigione, I., Miotti, S., Ciccone, E., Cantoni, C., Chen, Q., Colnaghi, M. I., and Moretta, L. Bispecific monoclonal antibodies directed to CD16 and to a tumor-associated antigen induce target-cell lysis by resting NK cells and by a subset of NK clones. Int. J. Cancer, 48: 227-233, 1991.
8. Garrido, M. A., Perez, P., Titus, J. A., Valdayo, M. J., Winkler, D. F., Barbieri, S. A., Wunderlich, J. R., and Segal, D. M. Targeted cytotoxic cells in human peripheral blood lymphocytes. J. Immunol., 144: 2891-2898, 1990.
9. Renner, C., Jung, W., Sahin, U., Denfeld, R., Pohl, C, Trumper, L., Hartmann, F., Diehl, V., van, L. R., and Pfreundschuh, M. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science (Washington DC), 264: 833-835, 1994.
10. Jung, G., Ledbetter, J. A., and Muller, E. H. Induction of cytotoxicity in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates. Proc. Natl. Acad. Sci. USA, 84: 4611-4615, 1987.
11. Bohlen, H., Hopff, T., Manzke, O., Engert, A., Kube, D., Wickramanayake, P. D., Diehl, V., and Tesch, H. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T-cells activated with CD3 × CD19 bispecific antibodies in combination with bivalent CD28 antibodies. Blood, 82: 1803-1812, 1993.
12. Mosier, D. E. Adoptive transfer of human lymphoid cells to severely immunodeficient mice: models for normal human immune function, autoimmunity, lymphomagenesis, and AIDS. Adv. Immunol., 50: 303-325, 1991.
13. Hoffmann-Fezer, G., Kranz, B., Gall, C., and Thierfelder, S. Peritoneal sanctuary for human lymphopoiesis in SCID mice injected with human peripheral blood lymphocytes from Epstein-Barr virus-negative donors. Eur. J. Immunol., 22: 3161-3166, 1992.
14. Rowe, M., Young, L. S., Crocker, J., Stokes, H., Henderson, S., and Rickinson, A. B. Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J. Exp. Med., 173: 147-158, 1991.
15. De Felice, M., Giarrusso, P. C., Lamberti, A., Turco, M. C., Valerio, G., van Lier, R. A., Yang, S. Y., Ferrone, S., and Venuta, S. Mitogenic activity of anti-CD28 MoAb CLB-CD28/1 on peripheral blood mononuclear cells and its cooperation with other anti-T cells MoAb in the activation of purified T lymphocytes. Tissue Antigens, 36: 12-18, 1990.
16. Bohlen, H., Manzke, O., Patel, B., Moldenhauer, G., Dorken, B., von, F. V., Diehl, V., and Tesch, H. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies. Cancer Res., 53: 4310-4314, 1993.
17. Reinhold, U., Abken, H., Kukel, S., Moll, M., Muller, R., Oltermann, I., and Kreysel, H. W. CD7-T cells represent a subset of normal human blood lymphocytes. J. Immunol., 150: 2081-2089, 1993.
18. + T lymphocytes. J. Immunol., 148: 1985-1992, 1992.
19. Harding, F. A., McArthur, J. G., Gross, J. A., Raulet, D. H., and Allison, J. P. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature (Lond.), 356: 607-609, 1992.
20. Freedman, A. S., Freeman, G. J., Rhynhart, K., and Nadler, L. M. Selective induction of B7/BB-1 on interferon-gamma stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway. Cell Immunol., 137: 429-437, 1991.
21. Kube, D., Platzer, C., von Knethen, A., Straub, H.. Bohlen, H., Hafner, M., and Tesch, H. Isolation of the human interleukin 10 promoter. Characterization of the promoter activity in Burkitt's lymphoma cell lines. Cytokine, 7: 1-7, 1995.
22. List, A. F., Greco, F. A., and Vogler, L. B. Lymphoproliferative diseases in immunocompromised hosts: the role of Epstein-Barr virus. J. Clin. Oncol., 5: 1673-1689, 1987.
23. Papadopoulos, E. B., Ladanyi, M., Emanuel, D., Mackinnon, S., Boulad, F., Carabasi, M. H., Castro-Malaspina, H., Childs, B. H., Gillio, A. P., Small, T. N., Joung, J. U., Kernan, N. A., and O'Reilly, R. J. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med., 330: 1185-1191, 1994.
24. Mackinnon, S., Papadopoulos, E. B., Carabasi, M. H., Reich, L., Collins, N. H., Boulad, F., Castro-Malaspina, H., Childs, B. H., Gillio, A. P., Kernan, N. A., Small, T. N., Young, J. W., and O'Reilly, R. J. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood, 86: 1261-1268, 1995.